Jackie on for Jason Simanski's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Jason Simanski at Bank of America asked about expectations for first-line use of aficamtan following the MAPLE data and the likely receptiveness of prescribers and payers.
Answer
President and CEO Robert Blum noted the MAPLE data will be novel and should inform treatment conversations. Fady Malik, EVP of R&D, and Andrew Callos, EVP & CCO, added that while immediate first-line use is unlikely due to payers, the data should elevate aficamtan in guidelines and accelerate its use as an add-on therapy.